Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials
- 24 June 2019
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 103 (3) , 255-267
Abstract
Objective A post‐hoc analysis of two phase III trials was carried out to explore the influence of age and treatment factors on the effect of bortezomib consolidation on progression‐free survival (PFS) post‐autologous stem cell transplantation (ASCT). Methods Patients with newly diagnosed multiple myeloma were assigned to one of two trials (ClinicalTrials. gov IDs: NCT00416273, NCT00416208), which were conducted in parallel, based on age (18–60 or 61–75 years, respectively). Following induction and ASCT, patients were randomized 1:1 to four 35‐day cycles of bortezomib consolidation (1.6 mg/m2 IV on days 1, 8, 15, 22) or observation only. Results Median PFS with bortezomib consolidation versus observation was 33.6 versus 29.0 months (P = 0.3599) in patients aged 18–60 years (n = 202), and 33.4 versus 26.4 months (P = 0.0073) in patients aged 61–75 years (n = 155), respectively. Bortezomib consolidation post‐ASCT appeared to equalize outcomes between older and younger patients who received prior treatment of differing intensity. This suggests that the effect of consolidation may be relative and may depend on the composition and intensity of induction and high‐dose therapy. Conclusion Older patients receiving less intensive prior treatment could experience a larger PFS benefit from bortezomib consolidation.Keywords
This publication has 42 references indexed in Scilit:
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myelomaLeukemia, 2017
- Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2017
- Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trialLeukemia, 2017
- Next-Generation Sequencing Informing Therapeutic Decisions and Personalized ApproachesAmerican Society of Clinical Oncology Educational Book, 2016
- The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myelomaEuropean Journal of Haematology, 2014
- Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsBlood, 2013
- Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialBlood, 2013
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaBlood, 2012
- Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysisAmerican Journal of Hematology, 2008